Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DRC +/- Bortezomib in Waldenström's Macroglobulinemia
NCT01788020Phase 3Completed
- Sponsor
- Ulm University
- Start
- Nov 2013
- Primary completion
- Nov 2018
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of bortezomib in Waldenström's macroglobulinemia (WM), sponsored by Ulm University. Started Nov 2013; status: completed.
02
Drugs
bortezomib
03
Conditions
Waldenström's macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT01788020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01788020.